TECHNICAL ADVANCES

A Living Organoid Biobank of Crohn's Disease Patients Reveals Distinct Clinical Correlates of Molecular Disease Subtypes

Short Title: Crohn's PDOs Reflect Clinical Trajectories

Authors:

Harrison M. Penrose[2,3], Saptarshi Sinha[1], Courtney Tindle[1,2], Kameron Zablan[3], Helen N. Le[3], Jennifer Neill[3], Pradipta Ghosh[1,2, 3†¶], and Brigid S. Boland[3†¶]

Affiliations:

[1]Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, 92093.

[2]HUMANOID™ Center of Research Excellence (CoRE), University of California San Diego, La Jolla, CA, 92093.

[3]Department of Medicine, University of California San Diego, La Jolla, CA, 92093.

Keywords: Patient-derived organoids, inflammatory bowel disease, personalized therapeutics, predictive disease models

†Senior corresponding authors:

Pradipta Ghosh, M.D.; prghosh@ucsd.edu

Brigid S. Boland, M.D.; bboland@health.ucsd.edu

GRANT SUPPORT

Funding for this work was supported by the Leona M. and Harry B. Helmsley Charitable Trust (to P.G.). Other sources of support include National Institutes of Health (NIH) grants AI141630, UG3TR003355 and AI55696 to P.G.; NIH grants P30DK120515 to B.S.B. H.M.P. was supported by The California Institute of Regenerative Medicine Training Grant for Clinical Fellows through Sanford-Burnham Prebys-UC San Diego. S.S. was supported by the American Association of Immunologists Intersect Fellowship Program for Computational Scientists and Immunologists.

LIST OF ABBREVIATIONS

Adult stem cell–derived organoids, AdSC; Crohn's disease, CD; Extraintestinal manifestations, EIM; Inflammatory Bowel Disease, IBD; Ileocecal, IC; Immune-Deficient Infectious CD, IDICD; Kyoto Encyclopedia of Genes and Genomes; KEGG; Non-stricturing, non-penetrating, NSNP; Patient-derived organoids, PDOs; Patient-reported outcomes, PRO; Stress and Senescence-Induced Fibrostenotic CD, S2FCD; Simple endoscopic score for Crohn's disease, SES-CD; Ulcerative colitis, UC; Univariate logistic regression, UV.

AUTHOR CONTRIBUTIONS

H.M.P., S.S., C.T., B.S.B., and P.G. conceptualized, supervised, and administered the project. B.S.B and P.G acquired funding to support it. Computational analyses were carried out by S.S. under the supervision of P.G. K.Z., H.N.L., J.N., and B.S.B provided key resources for human subjects and were responsible for the selection and enrollment of patients into this study. H.M.P., S.S., and P.G. prepared figures for data visualization. H.M.P., B.S.B, and P.G. wrote the original draft. H.M.P, S.S., C.T., B.S.B, and P.G. reviewed and edited the draft. All co-authors approved the final version of the manuscript.

COMPETING INTERESTS

BSB has received research grants from Merck, Mirador, Gilead and served as a consultant for Abbvie, Merck, and Celltrion.

RESOURCE AVAILABILITY

Lead Contacts: Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contacts, Pradipta Ghosh (prghosh@ucsd.edu) and Brigid S. Boland (bboland@health.ucsd.edu).

Materials availability: This study utilizes data generated from an organoid biobank. These materials are available from the lead contact with a completed Materials Transfer Agreement and patented technology agreement (Ghosh) following the guidelines of the Regents of the University of California, San Diego.

Data and code availability: Newly generated transcriptomic datasets of PDOs from the colons of patients with CD have been deposited in NCBI's GEO functional genomic repository under accession number

GSE293539. This paper did not generate or use custom computer codes. Any additional information required to reanalyze the data reported in this work is available from the lead contact upon request.

ACKNOWLEDGEMENTS

We apologize to those whose work could not be cited due to space limitations.

WORD COUNT: 999

GRAPHICAL ABSTRACT



In this prospective study, Penrose et al. evaluate a living biobank of genotyped and phenotyped patient-derived organoids (PDOs) as predictive tools in Crohn's disease, demonstrating their ability to faithfully capture past, present, and future disease behavior, and advancing PDO-informed precision medicine beyond oncology and into complex inflammatory disorders.

TECHNICAL ADVANCES

Inflammatory Bowel Diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic, relapsing disorders of the gastrointestinal tract without a cure or ideal preclinical model[1]. CD is particularly heterogeneous, with unpredictable trajectories and variable treatment responses[2]. While genetics explain some features (e.g., disease location), they poorly predict behavior, complications, or treatment outcomes—underscoring the need for personalized approaches.

We leveraged our previously described biobank of adult stem cell–derived **colonic** organoids (AdSC-PDOs) generated from biopsies of 24 prospectively followed CD patients[3]. Focusing on the colon (involved in ~60–70% of CD cases) and using AdSCs to retain tissue identity and epigenetic memory[4], we previously identified two consistent molecular subtypes: (i) *Immune-Deficient Infectious CD (IDICD)*, marked by impaired pathogen clearance, paradoxical immunosuppression, and CD-risk alleles (NOD2, ATG16L1), and (ii) *Stress and Senescence-Induced Fibrostenotic CD (S2FCD)*[3], defined by epithelial senescence, profibrotic signaling, and YAP1–IL-18 pathway mutations. These subtypes showed distinct morphologies, transcriptomes, and non-overlapping treatment responses independent of anatomical location (i.e. right vs left colon), inflammation status (i.e. inflamed vs uninflamed), or disease activity state (i.e. active vs inactive CD). Here, by integrating multi-omics with clinical data, we now demonstrate that **colonic** PDOs can predict disease subtype and trajectory. Our findings establish the fidelity of colonic PDOs as dynamic, outcome-predictive tools that bridge molecular classification and disease trajectory—bringing precision medicine in CD into sharper focus.

We first compared *IDICD* and *S2FCD*-PDOs to identify subtype-specific genes, pathways, and biological processes (**Fig 1A, B**; **Table S1**). Relevant to IBD, *IDICD* showed upregulation of genes involved in inflammation-immune regulation (*IL33, F2RL1*), sulfation pathway enzymes (*SULT1A4, PAPSS2*), and epithelial-stem cell maintenance (*KLF4*). Whereas *S2FCD* demonstrated enrichment of genes related to Wnt signaling and development (*WNT6, NOTUM*), epithelial barrier integrity (*LCN2, CDH11*), and immune activation (*CD40, TNFRSF6B*) (**Fig 1A**). A KEGG pathway enrichment analysis showed unique enrichment of biological pathways for each molecular subtype (**Fig 1B**). As predicted, *S2FCD* showed enrichment in Wnt and cytokine signaling consistent with senescence and a senescence-associated secretory phenotype, or SASP. Surprisingly, despite their derivation from the colon, *IDICD* was associated with retinol metabolism, and bile acid-related pathways—processes typically restricted to the ileum[5]. These findings support *IDICD* and *S2FCD* as biologically distinct epithelial subtypes of CD, each defined by discrete transcriptional programs and pathway enrichment that may reflect unique mechanisms and influence clinical presentation.

To assess whether the biologically distinct PDO subtypes (*IDICD* and *S2FCD*) correlate with clinical outcomes, we performed univariate logistic regression (UV) across a comprehensive dataset (**Table S1)**. This approach evaluated how each subtype (predictor) influenced clinical outcomes ranging from binary events (e.g., prior history of surgery) to ordinal measures (e.g., Simple Endoscopic Score [SES] of disease severity). Significant relationships between the two variables estimate the probability of the outcome based on the CD-PDO subtype. Despite the broad scope of variables, *IDICD* showed strong, significant associations

with prior ileocecal surgery, ileal disease activity (via SES-CD) and penetrating disease behavior (B3) at time of biopsy collection and organoid derivation, as well as lack of symptom improvement (via PROs) over the five year prospective follow-up period (**Fig 1C**). In contrast, *S2FCD* correlated with colonic disease activity at time of biopsy collection (total colonic SES-CD) (**Fig 1C**). Three other variables trended towards significance ($p<0.1$, indicative of a <10% probability that the observed relationship is due to random chance): *IDICD* was linked to ileal disease progression, while *S2FCD* was associated with a non-stricturing, mucosa-restricted colonic CD phenotype (non-stricturing, non-penetrating; NSNP CD) predominantly isolated to the colon ($p<0.1$). These results suggest *IDICD* aligns with progressive ileal disease, while *S2FCD* reflects isolated colonic inflammation. Multivariate analysis of key UV covariates revealed no independent associations, indicating high interdependence among variables (**Supplementary Figure 1**).

The emergence of strong associations between *IDICD* and key clinical outcomes—even in a small cohort—suggests meaningful links to prior surgery, current endoscopic activity, and future disease progression. Notably, our PDO cohort (25% ileal, 46% ileocolonic, 29% colonic) reflects real-world CD distribution[6]. Univariate analysis supports a potential causal role for *IDICD*-subtype in ileal disease, while multivariate modeling suggests that the subtype influences the entire disease continuum—past, present, and future—indistinguishably.

Our key discovery is that two molecular subtypes of **colon-derived** CD PDOs—*IDICD* and *S2FCD*—map onto distinct clinical phenotypes: *IDICD* tracks with **ileal disease**, including surgical history and disease progression, while *S2FCD* aligns with **colonic disease**. These findings elevate colonic PDOs from experimental models to **dynamic, predictive tools** for patient stratification and therapeutic testing, analogous to the role of PDOs in oncology.

There are three major takeaways. First, our work suggests colonic epithelium can serve as a **surrogate for ileal disease**, with epithelial immune dysfunction in *IDICD* potentially driving isolated ileal or ileocolonic CD. Mechanistically, both systemic (e.g., cytokine/hormonal) and local (e.g., microbial) pathways may be involved. Second, despite focusing on colonic epithelium, our findings converge on a broader model proposed earlier: CD is best stratified into ileal-dominant or colonic-dominant diseases (**Fig 1D**). Prior studies have shown genetic (e.g., NOD2, ATG16L1, MHC), stromal, transcriptomic, epigenomic, fecal composition, immune, and epidemiologic differences by disease location. Our PDO-based classification introduces a functional, epithelial-centric framework that complements these views. Third, these distinctions may imply rationale for location-based treatment responses, providing basis for future research. *IDICD*'s impaired cytokine response[3] may underlie ileal CD's poor response to anti-cytokine therapies (e.g., anti-TNFα, anti-IL12/23)[7], and instead support pro-clearance strategies (e.g., dual PPARα/γ agonists)[3, 8, 9]. Conversely, *S2FCD*'s senescence and oxidative stress signatures may explain colonic CD's responsiveness to senomorphics, e.g., JAK inhibitors (such as Pacritinib)[3]. These insights underscore the potential for precision-guided therapy in CD, guided by PDO-based subtyping.

While the cohort was relatively small, it reflected key CD subtypes and showed consistent findings across patients. A larger and longitudinally tracked cohort would strengthen validation. We do not dissect the full mechanistic links between colonic epithelial dysfunction and ileal disease but highlight a compelling direction for future research. Nonetheless, our study identifies clinically meaningful correlates of epithelial dysfunction, supporting the use of PDOs to enable mechanism-based, individualized therapies in Crohn's disease.

FIGURE AND LEGEND



Figure 1. **Colonic PDOs hint at distinct pathophysiology and outcomes in ileal versus colonic CD.**

(A) *Left*: Workflow in creating a 'living biobank' of colonic PDOs with prospective follow-up on disease outcomes. *Right*: Volcano plot depicting DEGs from RNA-seq in *IDICD* vs. *S2FCD*, where the interrupted line marks log2FC = 1.0. For clarity, gene symbols are shown only for the most interesting genes relevant to CD/IBD.

(B) Lollipop Bar Plots of KEGG pathways associated with DEGs [log2FC ≥ 1.5] in A.

(C) Univariate analysis models of *IDICD* vs. *S2FCD* subtypes as a linear combination of all variables in a CD cohort. The coefficient of each variable (at the center) with 95% CI (as error bars) and the p values are illustrated. The p-value for each term tests the null hypothesis that the coefficient is equal to zero (no effect). .p ≤ 0.1; *p ≤ 0.05; **p ≤ 0. 01. Bold = significant co-variates. See **Supplementary Figure S1** for multivariate analysis among the significant covariates. SES-CD, Simple endoscopic score for Crohn's Disease; IC, ileocecal; EIM, extraintestinal manifestations. Montreal classification for disease behavior: L1 – ileal, L2 – colonic, L3 – ileocolonic; B1 – non-stricturing, non-penetrating; B2 – stricturing; B3 – penetrating. Δ refers to the delta change between baseline and follow-up SES-CD or PRO scores over a prospective five year follow-up period. Behavior at collection refers to Montreal classification at time of biopsy; here, IDICD is linked to penetrating disease (B3).

(D) Schematic summarizes a focused, pertinent literature review that converges on the notion that all CDs, regardless of how they were evaluated across scales—genetic, epigenetic, cellular, exposome (stool composition), or clinical/epidemiologic correlates—appear to be broadly classifiable as ileal and/or ileocolonic vs. isolated colonic disease. Colon-focused analyses that consistently arrive at that conclusion, even when uninvolved, are highlighted. Manuscripts were selected based on their analysis of disease location and molecular or clinical phenotyping, with emphasis on studies evaluating colonic tissue.

SUPPLEMENTAL INFORMATION

Primary supplemental PDF: Supplemental figure and legend (**Supplementary Figure S1**), Supplemental methods, supplemental references.

Table S1: Differentially expressed genes between *IDICD* and *S2FCD* molecular subtypes of CD (tab 1); Patient characteristics of CD patients analyzed in univariate and multivariate analyses (tab 2).

REFERENCES

1. Baumgart DC, Le Berre C. Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease. N Engl J Med 2021;385:1302-1315.
2. Torres J, Mehandru S, Colombel JF, et al. Crohn's disease. Lancet 2017;389:1741-1755.
3. Tindle C, Fonseca AG, Taheri S, et al. A living organoid biobank of patients with Crohn's disease reveals molecular subtypes for personalized therapeutics. Cell Rep Med 2024;5:101748.
4. Zhao D, Ravikumar V, Leach TJ, et al. Inflammation-induced epigenetic imprinting regulates intestinal stem cells. Cell Stem Cell 2024;31:1447-1464 e6.
5. Geng T, Bao S, Sun X, et al. A clarification of concepts related to the digestion and absorption of carotenoids and a new standardized carotenoids bioavailability evaluation system. Food Chem 2023;400:134060.
6. Mills S, Stamos MJ. Colonic Crohn's disease. Clin Colon Rectal Surg 2007;20:309-13.
7. Atreya R, Bojarski C, Kuhl AA, et al. Ileal and colonic Crohn's disease: Does location makes a difference in therapy efficacy? Curr Res Pharmacol Drug Discov 2022;3:100097.
8. Sahoo D, Swanson L, Sayed IM, et al. Artificial intelligence guided discovery of a barrier-protective therapy in inflammatory bowel disease. Nat Commun 2021;12:4246.
9. Katkar GD, Sayed IM, Anandachar MS, et al. Artificial intelligence-rationalized balanced PPARalpha/gamma dual agonism resets dysregulated macrophage processes in inflammatory bowel disease. Commun Biol 2022;5:231.